# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $23 price tar...
Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage drug platform company developing novel ...
Rodman & Renshaw initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target of $67.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target ...